Cargando…

Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years

BACKGROUND: Infliximab has shown benefit in Crohn’s disease (CD) and ulcerative colitis (UC). OBJECTIVE: Evaluation of long-term outcome of therapy for both diseases. METHODS: We analyzed retrospectively patients treated at infusion centers from one institution. Demographic, laboratory parameters le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzafiri, Raed, Holcroft, Christina A, Malolepszy, Paula, Cohen, Albert, Szilagyi, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108681/ https://www.ncbi.nlm.nih.gov/pubmed/21694867 http://dx.doi.org/10.2147/CEG.S16168

Ejemplares similares

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
por: Viscido, Angelo, et al.
Publicado: (2019)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
por: Seo, Hyun Il, et al.
Publicado: (2014)

Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
por: Puthoor, Pamela R., et al.
Publicado: (2013)

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
por: Zhou, Ting, et al.
Publicado: (2021)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
por: Adibi, Peyman, et al.
Publicado: (2011)

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
por: Lawlor, Garrett, et al.
Publicado: (2009)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis
por: Mirza, Muhammad, et al.
Publicado: (2018)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis
por: Chapman, Christopher G., et al.
Publicado: (2014)

Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
por: Démaris, Alix, et al.
Publicado: (2022)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
por: Konikoff, Tom, et al.
Publicado: (2023)

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
por: Kim, Eun Hye, et al.
Publicado: (2015)

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study
por: Minami, Naoki, et al.
Publicado: (2015)

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis
por: Gheorghe, Cristian, et al.
Publicado: (2019)

Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
por: Pękala, Anna, et al.
Publicado: (2021)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn’s disease in adults with moderate-to-severe disease
por: Nag, Arpita, et al.
Publicado: (2022)

Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
por: De Cristofaro, Elena, et al.
Publicado: (2022)

Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3u34h38qls2eg49qcnja6uucgg